Navigation Links
Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
Date:4/8/2009

ATLANTA, April 8 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase 3 clinical trials for the use of Iluvien(TM) in the treatment of diabetic macular edema (DME) under the current protocol, without change. The Board completed its final review of the currently available safety and efficacy data prior to the readout in October 2009. A DSMB provides an independent evaluation of all trial data to identify potential safety issues that might warrant modification or early termination of ongoing clinical studies.

These clinical trials, known collectively as the FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), consist of two 36-month, doublemasked, randomized, multi-center trials in the U.S., Canada, Europe and India in support of a planned global registration filing. Safety and efficacy will be assessed after 24 months of follow-up, which will occur in October of this year.

"Alimera is pleased that the DSMB recommended the continuation of the FAME Study without change," said Alimera CEO Dan Myers. "We are looking forward to the last patient, last visit for the 24-month readout scheduled in October later this year."

Iluvien is an intravitreal insert being developed for the treatment of DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Each Iluvien insert is designed to provide a sustained therapeutic effect, up to 36 months for the low dose and up to 24 months for the high dose. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intra
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
2. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
3. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
4. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
8. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
9. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
10. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... HAIKOU, China, May 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Pharma ... Pharma" or the "Company"), a leading fully-integrated specialty pharmaceutical ... Financial Officer, Mr. Frank Waung, has been invited to ... in New York City on May 17, 2011. Conference ...
... China, May 13, 2011 /PRNewswire-Asia/ -- Winner Medical Group ... leading manufacturer of medical dressings, medical disposables and non-woven ... today announced it will attend the Oppenheimer 5th Annual ... NY. Winner Medical will present on Tuesday, May 17th ...
Cached Medicine Technology:China Pharma Holdings, Inc. to Present at the Eighth Annual Piper Jaffray China Growth Conference in New York on May 17, 2011 2Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference 2Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference 3
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... Efficient Operation for Gateway Healthcare , , PROVIDENCE, ... announced today that it is addressing the complex ... with the unique, next generation voice product, Cox Business ... its telecommunications services from a competitive provider to Cox ...
... marrow registry is free June 8-22; The Jeff Gordon Foundation seeds ... , MINNEAPOLIS, June 8 Every day, thousands of people ... Registry for a bone marrow match. To highlight the enormous need ... , the new name for the National Marrow Donor Program(R) Registry, ...
... ... market today, is now available to more doctors and health care professionals in Missouri through ... ... non-invasive and oral-based lead testing product in the market today, is now available to more ...
... ... sensors sizes up to 1.3 - inch format. , ... Van Nuys, CA (PRWEB) June 8, 2009 -- Schneider Optics, a ... 24mm lens. This is the third new machine vision lens Schneider has introduced in 2009. ...
... under-represented in clinical cancer research published in high-impact journals, ... University of Michigan Comprehensive Cancer Center. Taking into ... women, studies included a smaller proportion of women than ... of cancer types that were not gender specific, including ...
... Perinatology as a Medical Specialty , , WHITE PLAINS, N.Y. ... the United States and worldwide has been seen through the eyes ... evaluate an infant,s health at birth. , , Yesterday marked ... of Dimes, the organization she worked for from 1959 until her ...
Cached Medicine News:Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 2Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 3Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 4Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 2Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 3Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 4Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 2Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 3Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 4Health News:Women under-represented in cancer research, U-M study finds 2Health News:March of Dimes Honors 100th Anniversary of Virginia Apgar 2Health News:March of Dimes Honors 100th Anniversary of Virginia Apgar 3
... articulation maintains full inter-changeability. Modular tibial components ... fit. The Maxim Knee system is ... with expanded options to address surgeon preferences ... for use in total knee replacements both ...
Tibial distractor...
Simple, stable knee positioning triangles for lower extremity surgery. The triangles are radiolucent, autoclavable, and use latex-free, sterile, disposable pads....
... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
Medicine Products: